Bolt Biotherapeutics company info

What does Bolt Biotherapeutics do?
Bolt Biotherapeutics (NASDAQ:BOLT) is a biotechnology company dedicated to revolutionizing cancer treatment through the development of its innovative immuno-oncology platforms. The company's flagship projects focus on harnessing the body's immune system to target and destroy cancer cells, leveraging its cutting-edge research in the field of Immune-Stimulating Antibody Conjugates (ISACs). Bolt Biotherapeutics aims to pioneer treatments that offer improved outcomes for patients with various types of cancer. With a commitment to innovation and patient care, Bolt Biotherapeutics is actively advancing its pipeline of potential cancer therapies, driven by a deep understanding of the complex interactions within the tumor microenvironment.
Bolt Biotherapeutics company media
Company Snapshot

Is Bolt Biotherapeutics a public or private company?

key
Ownership
Public

How many people does Bolt Biotherapeutics employ?

people
Employees
100

What sector is Bolt Biotherapeutics in?

pie chart
Sector
Health Care

Where is the head office for Bolt Biotherapeutics?

location pin
Head Office
Redwood City, United States

What year was Bolt Biotherapeutics founded?

founded flag
Year Founded
2015
What does Bolt Biotherapeutics specialise in?
/Immunotherapy Development /Cancer Treatments /BDC-1001 Drug /ISAC Technology /Clinical Trials /Biopharmaceutical Research

What are the products and/or services of Bolt Biotherapeutics?

Overview of Bolt Biotherapeutics offerings
A pioneering project focusing on immuno-oncology, aiming to harness the body's immune system to fight cancer more effectively.
Development of a next-generation bolt-on technology designed to enhance the efficacy of existing cancer therapies.
Creation of a unique platform for targeted drug delivery, especially for hard-to-reach tumors, improving treatment accuracy and reducing side effects.
Advancement in personalized cancer vaccine technology, tailoring treatments to individual patient's tumor markers for increased effectiveness.
Exploration of antibody-drug conjugates (ADC) utilizing cutting-edge linker technology for improved stability and tumor targeting.
Research into modulating the tumor microenvironment to support immune system access and activity against cancer cells.

Who is in the executive team of Bolt Biotherapeutics?

Bolt Biotherapeutics leadership team
  • Dr. Randall C. Schatzman Ph.D.
    Dr. Randall C. Schatzman Ph.D.
    CEO & Director
  • Dr. Edgar George Engleman M.D.
    Dr. Edgar George Engleman M.D.
    Founder & Independent Director
  • Mr. William P. Quinn
    Mr. William P. Quinn
    CFO & Secretary
  • Mr. Grant  Yonehiro C.F.A., M.B.A.
    Mr. Grant Yonehiro C.F.A., M.B.A.
    Chief Business Officer
  • Dr. Edith A. Perez M.D.
    Dr. Edith A. Perez M.D.
    Chief Medical Officer
  • Mr. Wesley  Burwell
    Mr. Wesley Burwell
    VP & Head of Human Resources
  • Dr. Nathan  Ihle Ph.D.
    Dr. Nathan Ihle Ph.D.
    Senior Vice President of Pharmaceutical Operations